Literature DB >> 22340049

[Association between CTLA-4 gene polymorphism and susceptibility to cervical cancer].

Hua Li1, Yi-feng Zhou, Hong-yan Guo, Tong Sun, Wen-hua Zhang, Dong-xin Lin.   

Abstract

OBJECTIVE: To investigate the association between CTLA-4 +49A/G polymorphisms and the risk of susceptibility to cervical cancer.
METHODS: A hospital-based case-control study was conducted. 314 cases with primary cervical cancer and 320 healthy controls were collected and genotyped by PCR-based RFLP for +49A/G polymorphisms in the CTLA-4 gene.
RESULTS: The A allele and AA genotype of CTLA-4 gene were 32.5% and 9.6% in the patients, and 25.8% and 5.6% in the controls, respectively. Subjects with CTLA-4 +49AA genotype conferred a higher risk of cervical cancer (OR = 2.06, 95%CI: 1.10 - 3.85; P = 0.024). However, the correlation between AA genotype in CTLA-4 polymorphisms and clinicopathological characteristics was not significant.
CONCLUSION: The results of this study suggest that CTLA4 gene is associated with cervical cancer risk and may be a susceptible gene of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22340049

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  3 in total

Review 1.  The association between cytotoxic T lymphocyte-associated antigen-4 and cervical cancer.

Authors:  Ping Liu; Li Xu; Yuan Sun; Zhiping Wang
Journal:  Tumour Biol       Date:  2013-12-10

2.  Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.

Authors:  Hongyuan Wan; Hangsheng Zhou; Yanyan Feng; Yongquan Chen; Lijie Zhu; Yuanyuan Mi
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  Association between cytotoxic T lymphocyte antigen-4 +49A/G, -1722T/C, and -1661A/G polymorphisms and cancer risk: a meta-analysis.

Authors:  Rui Geng; Fanglong Song; Xiao Yang; Peng Sun; Junzheng Hu; Chunhui Zhu; Binjie Zhu; Weimin Fan
Journal:  Tumour Biol       Date:  2013-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.